Last reviewed · How we verify
NCT06058936
Exercises Using Virtual Reality on Cancer Patients
NA trial testing exercises using virtual reality technology in Breast Cancer Female in 54 participants. Completed in 30 July 2024.
12 June 2024
Quick facts
| Lead sponsor | University of Hail |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 54 |
| Start date | 15 September 2023 |
| Primary completion | 12 June 2024 |
| Estimated completion | 30 July 2024 |
| Sites | 1 location across Saudi Arabia |
Drugs / interventions tested
- exercises using virtual reality technology
Conditions studied
- Breast Cancer Female — all drugs for Breast Cancer Female →
Sponsor
University of Hail
Who can join
Adults 40 to 70, female only, with Breast Cancer Female. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
in this study, a randomized controlled trial will be conducted to evaluate the effect of adding exercises using virtual reality on achievements in patients having breast cancer and conducted surgical treatment
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Using Virtual Reality Pablo Gaming in the Post-Operative Rehabilitation of Breast Cancer Patients: Randomized Controlled Trial.
Abdelmoniem Ibrahim A, Aly SM, Youssef ASA, Ragab MMM, et al · · 2024 · cited 6× · PMID 39768532 · DOI 10.3390/jcm13247609
Verify or expand the search:
- PubMed search for NCT06058936
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer Female
Currently open trials in the same condition.
- NCT07505797 — ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) · recruiting
- NCT07198724 — ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrin · Phase 1, PHASE2 · recruiting
- NCT07331506 — Validation of the Oncoliq Test for the Early Detection of Breast Cancer. · recruiting
- NCT07214883 — UCF MammoChat: Image Repository · recruiting
- NCT07120100 — Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Surviv · NA · recruiting
Other University of Hail trials
Trials by the same sponsor.
- NCT07444125 — Two-leg Rotation and Sciatica · NA · not yet recruiting
- NCT07198204 — Different Hold Durations in Isometric Exercises · NA · not yet recruiting
- NCT07354451 — Pelvic Nerve Mobilization for Primary Dysmenorrhea · NA · recruiting
- NCT07215286 — Comparative Study on SNAG From Different Positions Low Back Pain Treatment · NA · not yet recruiting
- NCT06859905 — Blood Flow Restriction Training on Upper Limb Performance · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06058936 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Hail
- Last refreshed: 7 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06058936.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing